See more : Holiday Island Holdings, Inc. (HIHI) Income Statement Analysis – Financial Results
Complete financial analysis of ProQR Therapeutics N.V. (PRQR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ProQR Therapeutics N.V., a leading company in the Biotechnology industry within the Healthcare sector.
- Rhinomed Limited (RNO.AX) Income Statement Analysis – Financial Results
- Ticon Freehold and Leasehold Real Estate Investment Trust (FTREIT.BK) Income Statement Analysis – Financial Results
- Zydus Wellness Limited (ZYDUSWELL.BO) Income Statement Analysis – Financial Results
- Global Longlife Hospital and R (GLHRL.BO) Income Statement Analysis – Financial Results
- Interra Copper Corp. (IMIMF) Income Statement Analysis – Financial Results
ProQR Therapeutics N.V. (PRQR)
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.51M | 4.04M | 1.35M | 0.00 | 1.93M | 4.94M | -1.53M | 2.28M | 9.41M | 313.00K | 0.00 |
| Cost of Revenue | 133.52K | 2.48M | 0.00 | 2.19M | 116.82M | 983.51K | 1.00M | 1.28M | 482.85K | 0.00 | 0.00 |
| Gross Profit | 6.38M | 1.56M | 1.35M | -2.19M | -114.89M | 3.96M | -2.53M | 1.00M | 8.92M | 313.00K | 0.00 |
| Gross Profit Ratio | 97.95% | 38.68% | 100.00% | 0.00% | -5,943.61% | 80.09% | 165.49% | 43.84% | 94.87% | 100.00% | 0.00% |
| Research & Development | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.40M | 10.27M | 2.57M |
| General & Administrative | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M | 6.51M | 786.00K |
| Other Expenses | -3.01M | -765.00K | -1.04M | 9.37M | 1.93M | 5.76M | 1.50M | 1.83M | 3.24M | 313.00K | 0.00 |
| Operating Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Cost & Expenses | 38.37M | 68.75M | 58.55M | 51.82M | 59.38M | 42.05M | 41.99M | 41.40M | 30.24M | 16.77M | 3.24M |
| Interest Income | 2.59M | 106.00K | 5.00K | 313.00K | 402.00K | -792.00K | -3.18M | 470.00K | 6.17M | 4.33M | 24.00K |
| Interest Expense | 1.20M | 5.13M | 3.41M | 2.04M | 1.08M | 810.00K | 596.00K | 538.00K | 395.00K | 265.00K | 38.00K |
| Depreciation & Amortization | 2.51M | 2.48M | 2.42M | 2.19M | 2.05M | 983.51K | 1.00M | 1.28M | 480.00K | 126.00K | 24.00K |
| EBITDA | -24.10M | -56.46M | -54.95M | -136.56M | -174.27M | -35.29M | 0.00 | -120.55M | -84.24M | -49.70M | -3.19M |
| EBITDA Ratio | -369.93% | -1,470.99% | -4,089.81% | 0.00% | -2,965.65% | -831.05% | 2,676.78% | -1,759.68% | -316.34% | -5,318.85% | 0.00% |
| Operating Income | -31.86M | -64.72M | -57.19M | -42.37M | -57.45M | -36.29M | -40.50M | -39.57M | -27.00M | -16.46M | -3.24M |
| Operating Income Ratio | -489.09% | -1,603.07% | -4,223.86% | 0.00% | -2,971.81% | -734.53% | 2,648.66% | -1,734.14% | -287.05% | -5,259.11% | 0.00% |
| Total Other Income/Expenses | 4.05M | 1.05M | -3.47M | -4.12M | 117.65M | -792.00K | 850.31K | 470.00K | 6.17M | 4.33M | -14.00K |
| Income Before Tax | -27.81M | -64.80M | -61.56M | -46.49M | -56.61M | -37.09M | -43.67M | -39.10M | -20.83M | -12.13M | -3.25M |
| Income Before Tax Ratio | -426.97% | -1,605.03% | -4,546.75% | 0.00% | -2,928.82% | -750.56% | 2,856.31% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| Income Tax Expense | -78.00K | 96.00K | 117.00K | 124.00K | 132.00K | 1.00K | 2.00K | -470.00K | -6.17M | -4.33M | 24.00K |
| Net Income | -28.12M | -64.89M | -61.68M | -46.61M | -56.75M | -36.89M | -43.64M | -39.10M | -20.83M | -12.13M | -3.25M |
| Net Income Ratio | -431.67% | -1,607.41% | -4,555.39% | 0.00% | -2,935.64% | -746.69% | 2,853.96% | -1,713.54% | -221.45% | -3,874.44% | 0.00% |
| EPS | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| EPS Diluted | -0.35 | -0.91 | -0.96 | -0.93 | -1.38 | -1.08 | -1.72 | -1.67 | -0.89 | -1.09 | -0.15 |
| Weighted Avg Shares Out | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
| Weighted Avg Shares Out (Dil) | 81.01M | 71.64M | 64.18M | 50.06M | 41.04M | 34.05M | 25.37M | 23.35M | 23.34M | 11.08M | 22.21M |
Strength Seen in ProQR (PRQR): Can Its 7% Jump Turn into More Strength?
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index
ProQR Announces Upcoming Investor Conferences in November and December
ProQR Appoints Theresa Heggie as Chief Commercial Officer
Investment Case On ProQR Therapeutics Gets More Enticing
Implied Volatility Surging for ProQR (PRQR) Stock Options
Here's Why ProQR Stock Surged on Thursday
PRQR Stock: Why It Is Trading Higher Today
ProQR Announces Conference Call to Discuss the Axiomer® RNA Editing Platform
ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
Source: https://incomestatements.info
Category: Stock Reports